



## Irbesartan Teva

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
IB/0047	B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	01/09/2023		Annex II	
IB/0046/G	This was an application for a group of variations.  B.I.d.1.a.4 - Stability of AS - Change in the re-test	31/08/2023	n/a		

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>period/storage period - Extension or introduction of a re-test period/storage period supported by real time data</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>				
IA/0044	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	14/06/2022	n/a		
IA/0043	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	14/06/2022	n/a		
IB/0042/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>	22/12/2021	n/a		
IB/0041	B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological	29/07/2021	24/02/2022	Annex II	Update of Annex II of the product information to lift condition D

	product) of a specification parameter with its corresponding test method as a result of a safety or quality issue				
IB/0040/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>	29/06/2021	24/02/2022	SmPC and PL	
IAIN/0039	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	06/05/2021	24/02/2022	Annex II and PL	
IB/0038/G	This was an application for a group of variations.	06/05/2021	n/a		

	<p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>				
A31/0032	<p>The European Commission triggered a referral under Article 31 of Directive 2001/83/EC and requested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinal products and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked. During the CHMP plenary meeting in September 2018, the scope of the referral has been widened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan). The CHMP Opinion was issued on 31 January 2019 and the</p>	12/11/2020	19/02/2021	Annex II	<p>Please refer to the assessment report: Irbesartan Teva EMEA/H/A-31/1471/C/1093/0032</p>

	<p>Commission Decision was issued on 11 April 2019.</p> <p>In a letter dated 29 July 2020, the European Commission requested the EMA to assess the impact of the outcome of the Article 5(3) assessment on nitrosamines adopted on 25 June 2020 on the CHMP's opinion of 31 January 2019 for the scientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471). The CHMP was requested to give its recommendation whether the conditions of the Marketing Authorisations should be varied.</p>				
IA/0037	A.7 - Administrative change - Deletion of manufacturing sites	16/02/2021	24/02/2022	Annex II and PL	
IAIN/0036	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)	18/09/2020	n/a		
IB/0035/G	<p>This was an application for a group of variations.</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the</p>	21/11/2019		Annex II	

	relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation				
IAIN/0034/G	This was an application for a group of variations.  A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	19/12/2018	n/a		
IB/0033	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	23/10/2018	11/04/2019	SmPC and PL	
IA/0031	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	03/08/2017	n/a		
IA/0030	B.III.1.a.2 - Submission of a new/updated or	03/05/2017	n/a		

	deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer				
IB/0029	C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	31/08/2016	06/04/2017	SmPC, Labelling and PL	
IA/0028	A.7 - Administrative change - Deletion of manufacturing sites	30/03/2016	06/04/2017	Annex II and PL	
IB/0027	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	09/03/2016	n/a		
IB/0025	B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number	14/08/2015	n/a		
IB/0024	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	01/07/2015	n/a		
IA/0026	B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number	16/06/2015	n/a		
IB/0023/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of	08/01/2015	08/02/2016	Annex II and PL	

<p>manufacturing sites</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size</p> <p>B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size</p> <p>B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.e.7.a - Change in supplier of packaging</p>				
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--



	<p>components or devices (when mentioned in the dossier) - Deletion of a supplier</p> <p>B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation</p> <p>B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>				
IB/0021/G	This was an application for a group of variations.	17/12/2014	n/a		

	<p>B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer</p> <p>B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.z - Change in control of the AS - Other variation</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>				
T/0022	Transfer of Marketing Authorisation	04/11/2014	01/12/2014	SmPC,	

				Labelling and PL	
IAIN/0020/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	17/09/2014	01/12/2014	Annex II and PL	
A31/0017	<p>On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit-risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.</p>	22/05/2014	04/09/2014	SmPC and PL	For further information please refer to the Renin-angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report.

R/0019	Renewal of the marketing authorisation.	22/05/2014	18/07/2014		Renewal of the Marketing Authorisation with unlimited validity. Minor changes to the Product information have been implemented following QRD review.
IB/0018/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO</p>	20/01/2014	18/07/2014	SmPC, Annex II, Labelling and PL	

	new additional data is required to be submitted by the MAH				
IAIN/0016	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/05/2013	n/a		
IB/0015/G	<p>This was an application for a group of variations.</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>	01/03/2013	n/a		
II/0013/G	This was an application for a group of variations.	15/11/2012	15/11/2012		

	<p>A grouped application consisting of a type II and type IA variations:</p> <p>B.I.a.2.b – to add an alternative route of synthesis of the active substance</p> <p>B.I.a.1.a – to add an alternative manufacturing site of the active substance</p> <p>B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p>				
IAIN/0014/G	<p>This was an application for a group of variations.</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p>	18/10/2012	n/a		
IB/0011	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	20/07/2012	25/10/2012	SmPC and PL	

IAIN/0010/G	<p>This was an application for a group of variations.</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p>	30/04/2012	25/10/2012	SmPC, Labelling and PL	
IAIN/0009/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release</p>	30/11/2011	25/05/2012	Annex II and PL	
IA/0008/G	<p>This was an application for a group of variations.</p> <p>- To change the specifications of the active substance to comply with Ph. Eur.</p>	01/06/2010	n/a		

	<ul style="list-style-type: none"> <li>- To introduce minor changes to an approved test procedure of the finished product.</li> <li>- To introduce minor changes to an approved test procedure of the finished product.</li> <li>- To add a new supplier of aluminium foil for the primary packaging of the finished product.</li> </ul> <p>B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier</p>				
IA/0007	B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions	17/02/2010	n/a		
IA/0006	B.II.a.2.a - Change in the shape or dimensions of the pharmaceutical form - Immediate release tablets, capsules, suppositories and pessaries	17/02/2010	n/a		
IA/0005	B.II.b.4.a - Change in the batch size (including batch	17/02/2010	n/a		



	size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size				
II/0003	Changes relating to the irbesartan drug substance including addition of an alternative manufacturing process for an intermediate used in the synthesis of irbesartan and update of the active substance specification to include additional tests for the residual solvents.  Change(s) to the manufacturing process for the active substance	21/01/2010	09/02/2010		
IB/0004	IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing	27/01/2010	n/a	Annex II and PL	
IA/0002	IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site	17/11/2009	n/a		
IA/0001	IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits	17/11/2009	n/a		